Effects of Paliperidone on Serum D-dimer Levels: Clinical and Experimental Findings.

BACKGROUND

Dysregulation of coagulation function associated with antipsychotic treatment remains poorly understood. This study investigates the potential impact of paliperidone on serum D-dimer levels during the early stages of treatment.

METHODS

Nine patients diagnosed with first-episode schizophrenic spectrum disorder were assessed for serum D-dimer levels before and after a 2-week paliperidone regimen. Additionally, eight adult C57 mice in the experimental group (EG) received 3 mg/kg of paliperidone daily for 10 consecutive days, while eight mice in the control group (CG) were untreated. Venous blood was collected and analyzed for D-dimer at baseline, and on the 5th and 10th days in the EG, as well as on the 10th day for the CG.

RESULTS

No significant differences were observed in serum D-dimer levels before and after paliperidone treatment in the patient cohort. In animal experiments, compared to the CG on the 10th day, serum D-dimer levels in the EG on the 10th day showed no significant difference (p > 0.05), while the level in the EG on the 5th day was significantly lower (p < 0.05). Compared to its baseline, serum D-dimer levels within the EG on the 5th day was significantly decreased (p < 0.05).

CONCLUSION

Short-term paliperidone treatment had minimal effects on serum D-dimer levels in both human participants and mice, though transient changes were noted early in treatment. Nonetheless, the potential for drug-induced coagulation disruption should be considered in clinical practice.